Antibiotic susceptibility testing and the non-inferiority margin: key considerations when interpreting vonoprazan-amoxicillin dual therapy trials
Journal of the Formosan Medical Association · 2026-05
DOI: 10.1016/j.jfma.2026.05.034 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the Formosan Medical Association, 2026-05. Verfasst von Leyi Fei und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: 1304788379@qq.com. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- The Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: 1304788379@qq.com.
- Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: 20071029@zcmu.edu.cn.
Zitieren
APA
Fei, L., & Zhang, Q. (2026). Antibiotic susceptibility testing and the non-inferiority margin: key considerations when interpreting vonoprazan-amoxicillin dual therapy trials. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2026.05.034
Vancouver
Fei L, Zhang Q. Antibiotic susceptibility testing and the non-inferiority margin: key considerations when interpreting vonoprazan-amoxicillin dual therapy trials. Journal of the Formosan Medical Association. 2026. doi:10.1016/j.jfma.2026.05.034
BibTeX
@article{Fei2026,
author = {Fei, Leyi and Zhang, Quanai},
title = {Antibiotic susceptibility testing and the non-inferiority margin: key considerations when interpreting vonoprazan-amoxicillin dual therapy trials},
journal = {Journal of the Formosan Medical Association},
year = {2026},
doi = {10.1016/j.jfma.2026.05.034}
}
EUVIMED